THRESHOLD PHARMACEUTICALS, INC. (NASDAQ:THLD) Files An 8-K Regulation FD Disclosure

THRESHOLD PHARMACEUTICALS, INC. (NASDAQ:THLD) Files An 8-K Regulation FD Disclosure

Story continues below

Item 7.01

Regulation FD Disclosure.

Spokespersons of Threshold Pharmaceuticals, Inc. (the Company)
plan to present the information in the presentation slides
attached hereto as Exhibit 99.1.

The furnishing of the attached presentation is not an admission
as to the materiality of any information therein. The information
contained in the slides is summary information that is intended
to be considered in the context of more complete information
included in the Companys filings with the U.S. Securities and
Exchange Commission (the SEC) and other public announcements that
the Company has made and may make from time to time by press
release or otherwise. The Company undertakes no duty or
obligation to update or revise the information contained in this
report, although it may do so from time to time as its management
believes is appropriate. Any such updating may be made through
the filing of other reports or documents with the SEC, through
press releases or through other public disclosures. For important
information about forward looking statements, see the slide
titled Forward Looking Statements in Exhibit 99.1 attached
hereto.

The information in this Item7.01 of this Current Report on Form
8-K and Exhibit 99.1 attached hereto shall not be deemed filed
for purposes of Section18 of the Securities Exchange Act of 1934,
as amended, or otherwise subject to the liabilities of that
section or Sections 11 and 12(a)(2) of the Securities Act of
1933, as amended. The information contained in this Item7.01 and
in the presentation attached as Exhibit 99.1 to this Current
Report shall not be incorporated by reference into any filing
with the SEC made by the Company, whether made before or after
the date hereof, regardless of any general incorporation language
in such filing.

Item9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

No.

Description
99.1 Company slide presentation


About THRESHOLD PHARMACEUTICALS, INC. (NASDAQ:THLD)

Threshold Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. It is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib. Evofosfamide is designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not in healthy tissues. Tarloxotinib is under investigation in two Phase II proof-of-concept trials: one for the treatment of patients with mutant EGFR-positive, T790M-negative advanced NSCLC progressing on an EGFR TKI, and the other for patients with recurrent or metastatic squamous cell carcinomas of the head and neck. [18F]-HX4 is an investigational Positron Emission Tomography imaging agent for hypoxia to identify and quantify the degree of hypoxia in tumors in vivo.

THRESHOLD PHARMACEUTICALS, INC. (NASDAQ:THLD) Recent Trading Information

THRESHOLD PHARMACEUTICALS, INC. (NASDAQ:THLD) closed its last trading session up +0.009 at 0.539 with 843,769 shares trading hands.

An ad to help with our costs